(Q53160804)

12 May 2018

title

Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. (English)

1 reference

12 May 2018

main subject

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author

Athanasios D. Marinis

7

1 reference

12 May 2018

author name string

Katerina Malagari

1

1 reference

12 May 2018

Mary Pomoni

2

1 reference

12 May 2018

Hippocrates Moschouris

3

1 reference

12 May 2018

Evanthia Bouma

4

1 reference

12 May 2018

John Koskinas

5

1 reference

12 May 2018

Aspasia Stefaniotou

6

1 reference

12 May 2018

Alexios Kelekis

8

1 reference

12 May 2018

Efthymia Alexopoulou

9

1 reference

12 May 2018

Achilles Chatziioannou

10

1 reference

12 May 2018

Katerina Chatzimichael

11

1 reference

12 May 2018

Spyridon Dourakis

12

1 reference

12 May 2018

Nikolaos Kelekis

13

1 reference

12 May 2018

Spyros Rizos

14

1 reference

12 May 2018

Dimitrios Kelekis

15

1 reference

12 May 2018

publication date

22 May 2012

1 reference

12 May 2018

CardioVascular and Interventional Radiology

published in

1 reference

12 May 2018

volume

35

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

page(s)

1119-1128

1 reference

12 May 2018

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Drug-loaded microspheres for the treatment of liver cancer: review of current results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

New Insights into the Mechanisms of the Interactions Between Doxorubicin and the Ion-Exchange Hydrogel DC Bead™ for Use in Transarterial Chemoembolization (TACE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Major achievements in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-012-0394-0

10.1007/S00270-012-0394-0

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018